These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 25118484)
21. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718 [TBL] [Abstract][Full Text] [Related]
22. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses. van den Akker PA; Zusterzeel PL; Aalders AL; Snijders MP; Samlal RA; Vollebergh JH; Kluivers KB; Massuger LF Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):422-5. PubMed ID: 21824712 [TBL] [Abstract][Full Text] [Related]
23. The risk of malignancy index in discrimination of adnexal masses. Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665 [TBL] [Abstract][Full Text] [Related]
24. Calcifications in mucinous and serous cystic ovarian tumors. Okada S; Ohaki Y; Inoue K; Kawamura T; Hayashi T; Kato T; Kumazaki T J Nippon Med Sch; 2005 Feb; 72(1):29-33. PubMed ID: 15834205 [TBL] [Abstract][Full Text] [Related]
25. Trans-vaginal ultrasound examination of ovarian masses in premenopausal women. Botta G; Zarcone R Eur J Obstet Gynecol Reprod Biol; 1995 Sep; 62(1):37-41. PubMed ID: 7493706 [TBL] [Abstract][Full Text] [Related]
26. Comparison of risk of malignancy indices in evaluating ovarian masses in a Southeast Asian population. Ong C; Biswas A; Choolani M; Low JJ Singapore Med J; 2013 Mar; 54(3):136-9. PubMed ID: 23546025 [TBL] [Abstract][Full Text] [Related]
27. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511 [TBL] [Abstract][Full Text] [Related]
28. Ovarian fibroma/fibrothecoma: retrospective cohort study shows limited value of risk of malignancy index score. Numanoglu C; Kuru O; Sakinci M; Akbayır O; Ulker V Aust N Z J Obstet Gynaecol; 2013 Jun; 53(3):287-92. PubMed ID: 23611791 [TBL] [Abstract][Full Text] [Related]
29. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. Dora SK; Dandapat AB; Pande B; Hota JP J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987 [TBL] [Abstract][Full Text] [Related]
30. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Lycke M; Kristjansdottir B; Sundfeldt K Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898 [TBL] [Abstract][Full Text] [Related]
31. Addition of parity to the risk of malignancy index score in evaluating adnexal masses. Yavuzcan A; Çağlar M; Özgü E; Üstün Y; Dilbaz S; Ozdemir I; Güngör T; Kumru S Taiwan J Obstet Gynecol; 2014 Dec; 53(4):518-22. PubMed ID: 25510694 [TBL] [Abstract][Full Text] [Related]
32. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Manjunath AP; Pratapkumar ; Sujatha K; Vani R Gynecol Oncol; 2001 May; 81(2):225-9. PubMed ID: 11330953 [TBL] [Abstract][Full Text] [Related]
33. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. Terzic M; Dotlic J; Likic I; Brndusic N; Pilic I; Ladjevic N; Maricic S; Arsenovic N; Maricic Z Taiwan J Obstet Gynecol; 2013 Jun; 52(2):253-7. PubMed ID: 23915860 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716 [TBL] [Abstract][Full Text] [Related]
35. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound. Arun-Muthuvel V; Jaya V Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927 [TBL] [Abstract][Full Text] [Related]
36. The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Mancuso A; De Vivo A; Triolo O; Irato S Eur J Gynaecol Oncol; 2004; 25(2):207-10. PubMed ID: 15032283 [TBL] [Abstract][Full Text] [Related]
37. Sonographic discrimination between benign and malignant adnexal masses in premenopause. Radosa MP; Vorwergk J; Fitzgerald J; Kaehler C; Schneider U; Camara O; Runnebaum IB; Schleußner E Ultraschall Med; 2014 Aug; 35(4):339-44. PubMed ID: 23775448 [TBL] [Abstract][Full Text] [Related]
38. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses? Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526 [TBL] [Abstract][Full Text] [Related]
39. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients. Li QL; Wang CJ; Qi P; Zhang YX Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641 [TBL] [Abstract][Full Text] [Related]
40. A comparative study of the risk of malignancy index and the ovarian crescent sign for the diagnosis of invasive ovarian cancer. Yazbek J; Aslam N; Tailor A; Hillaby K; Raju KS; Jurkovic D Ultrasound Obstet Gynecol; 2006 Sep; 28(3):320-4. PubMed ID: 16881074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]